Latest news:

Successful meeting with the German Medicines Agency regarding preparations for topical phase II scalp study

Follicum AB (“Follicum” or “company”) today report that the company has had a successful scientific advisory meeting regarding the hair project FOL-005, with the German authority, BfArM. In accordance with the previously announced timetable, Follicum has prepared a background document for scientific advice with the German Medicinces agency BfArM. The meeting discussed which additional toxicity […]

Sign up for our Newsletter

Follicum’s compliance with GDPR. Read more

Hair growth

Our drug candidate FOL-005 has, in clinical trials, demonstrated increased hair growth on healthy individuals

Read more


Follicums pre-clinical research has resulted in a new peptide class which increased the release of insulin on mice

Read more


We want to develop safe, effective and cost effective drugs, suitable for both men and women, that have minimal side effects

Read more




11 Nov 19
BIO Europe

Follicum will attend the BIO Europe conference in Hamburg 11-13 November 2019 More information will...